Study of endocrine markers involved in dedifferentiation and identification of C function or redifferentiate pancreatic β-cells in type 2 diabetes

Abraham Neelankal John

Research output: ThesisDoctoral Thesis

5 Downloads (Pure)


To enhance the knowledge of β-cell dedifferentiation (BCD) and its causal role in Type 2 diabetes (T2D), my studies employed β-cell line mouse insulinoma 6 (MIN6) and db/db islets from T2D model mice thereby establishing those as models of dedifferentiation. Vitamin D receptor (VDR)-targeted therapy that employed LCA propionate was utilized to treat early passage MIN6 and db/+ mice islets in the pre-diabetic state to protect β-cell from undergoing dedifferentiation. Furthermore, my research using MIN6 and db/db also identified a novel druggable compound ANJR12947285, which has the potential to induce redifferentiation in dedifferentiated β-cell.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • The University of Western Australia
Thesis sponsors
Award date20 Jul 2018
Publication statusUnpublished - 2018


Cite this